Quick Answer
Vir Biotechnology, Inc. reported Cash And Cash Equivalents At Carrying Value of $232.19 million for the year ending 2025.
- Vir Biotechnology, Inc. showed an increase of +4.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Vir Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $47.67 million | Q1 2019: $64.72 million | Q2 2019: $80.68 million | Q3 2019: $93.70 million | Q1 2020: $168.42 million | Q2 2020: $371.78 million | Q3 2020: $462.52 million | Q1 2021: $521.40 million | Q2 2021: $741.95 million | Q3 2021: $714.52 million | Q1 2022: $812.36 million | Q2 2022: $1.51 billion | Q3 2022: $963.74 million | Q1 2023: $824.91 million | Q2 2023: $666.95 million | Q3 2023: $452.10 million | Q1 2024: $160.71 million | Q2 2024: $296.86 million | Q3 2024: $168.35 million | Q1 2025: $273.57 million | Q2 2025: $211.10 million | Q3 2025: $170.08 million.
- Over the full 9 years of available data (2017 to 2025), Vir Biotechnology, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 23.6%.
- Historical annual values: Fiscal year 2025: $232.19 million | Fiscal year 2024: $222.95 million | Fiscal year 2023: $241.58 million | Fiscal year 2022: $848.63 million | Fiscal year 2021: $347.82 million | Fiscal year 2020: $436.58 million | Fiscal year 2019: $109.34 million | Fiscal year 2018: $47.60 million | Fiscal year 2017: $187.92 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: